{"filings":[{"id":1582957,"accession_number":"0001104659-26-082715","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2026-07-10T21:10:06+00:00","items":["5.02"],"status":"ready","headline":"DarioHealth extends President & CCO Steven Nelson's medical leave indefinitely","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steven Nelson, President and Chief Commercial Officer, on indefinite medical leave as of July 10, 2026.","Responsibilities assumed by senior management team; no replacement named.","Leave extended from temporary to indefinite; no return date given."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93488,"accession_number":"0001104659-26-042362","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"DarioHealth appoints veteran healthcare exec John R. Palumbo to board to support commercial scaling","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John R. Palumbo, age 75, appointed to DarioHealth board effective April 10, 2026.","Brings over 40 years healthcare experience incl. senior roles at AmerisourceBergen and Allscripts.","Appointment aims to accelerate commercial scaling and channel partnerships per CEO Erez Raphael.","Also serves on boards of Lucid Diagnostics (LUCD), PM Pediatrics, ivWatch, and QLess.","Will receive standard non-executive director fees; no material transactions to disclose."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105157,"accession_number":"0001104659-26-036834","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"DarioHealth enters $20M at-the-market equity distribution agreement with A.G.P./Alliance Global Partners","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company may issue and sell up to $20M of common stock through ATM program with A.G.P./Alliance Global Partners.","Commission of 3.00% of gross proceeds; reimbursement of expenses up to $35,000 plus quarterly fees.","Proceeds to be used for commercial activities, R&D, M&A, corporate activities, repayment of debt, and working capital.","Shares offered under effective S-3 registration statement filed March 19, 2026, effective March 27, 2026.","Company has no obligation to sell any shares and may suspend or terminate the agreement at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105156,"accession_number":"0001104659-26-009247","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"DarioHealth amends charter to allow board to alter bylaws; stockholder approval obtained Jan 29","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amended charter filed Feb 2, 2026 authorizes board to alter/repeal bylaws, subject to stockholder power.","Stockholders approved the amendment at annual meeting on January 29, 2026.","Governance change does not affect financials, operations, or outstanding shares.","Exhibit 3.1 contains the full Amended and Restated Certificate of Incorporation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105155,"accession_number":"0001104659-26-007974","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2026-01-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"DarioHealth shareholders approve all seven proposals at 2026 Annual Meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Directors elected: Hila Karah, Dennis Matheis, Dennis M. McGrath, Erez Raphael, Yoav Shaked, Lawrence Leisure, Adam K. Stern.","Ratified Kesselman & Kesselman (PwC) as auditor for FY 2026 (4,952,777 for, 17,242 against).","Approved conversion of 25,605 Series D/D-1/D-2/D-3 preferred shares into 1,697,843 common shares, plus dividend and lock-up shares.","Ratified issuance of common shares upon exercise of pre-funded warrants, warrants and RSUs from Twill acquisition.","Approved increase in equity incentive plan by 500,000 shares and charter amendment allowing board to amend bylaws."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121413,"accession_number":"0001104659-25-109166","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"DarioHealth amends credit facility; resets covenants, waives Q2/Q3 tests, adds $10M liquidity covenant","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Credit agreement amended with Callodine Commercial Finance on Nov 5, 2025.","Financial covenant testing waived for Q2 and Q3 2025; minimum unencumbered liquid assets set at $10M.","Additional $2.5M funding from lenders now uncommitted and discretionary; exit fee increased by $150k.","Warrant exercise price reduced from $16.556 to $15.3495; conversion price on up to $2.5M loan reduced to $15.3495.","Amendment fee of $150k paid; 13-week cash-flow reporting required when liquidity below $11M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138079,"accession_number":"0001104659-25-093431","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2025-09-25T23:59:59+00:00","items":["1.01","3.02","5.03","8.01","9.01"],"status":"ready","headline":"DarioHealth launches strategic review, raises $17.5M via private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board formed Special Committee, engaged Perella Weinberg as advisor to explore sale, merger, or standalone.","Raised $17.5M gross via private placement of 1.15M shares and 1.56M pre-funded warrants at $6.45/share.","Series C-1 Preferred mandatory conversion accelerated; holders receive common stock or pre-funded warrants plus dividends.","Offering closed September 23, 2025; net proceeds for general corporate purposes.","Strategic review follows multiple unsolicited inbound inquiries from interested parties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138078,"accession_number":"0001104659-25-091718","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2025-09-19T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"DarioHealth accelerates mandatory conversion of Series C & D preferred stock into common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective Sept 18, 2025: all outstanding Series C, C-2, D, D-1, D-2, D-3 preferred convert to common stock or pre-funded warrants at holder's election.","Series A-1 certificate amended to give holders option to receive pre-funded warrants instead of common stock on conversion.","Each holder also receives all accrued unpaid dividends, including PIK shares, subject to beneficial ownership blockers.","Amendments approved by majority of preferred holders and Board; no new securities issued or sold."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138077,"accession_number":"0001104659-25-089629","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"DarioHealth regains Nasdaq minimum bid price compliance; deficiency closed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Sep 12, 2025 confirming compliance with Rule 5550(a)(2).","Closing bid price at or above $1.00 for 10 consecutive days (Aug 28 to Sep 11, 2025).","The matter is now closed; no further action required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138076,"accession_number":"0001104659-25-082513","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2025-08-25T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"DarioHealth announces 20-for-1 reverse stock split effective August 28, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split at 20:1 ratio takes effect at market open on August 28, 2025.","Outstanding shares reduced from ~47,996,572 to ~2,399,829; authorized shares unchanged at 400M.","No fractional shares issued; fractional shares rounded up to nearest whole share.","Trading symbol DRIO unchanged; new CUSIP 23725P 308.","Proportional voting rights and dividends unaffected; options and warrants adjusted accordingly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138075,"accession_number":"0001104659-25-070069","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"DarioHealth shareholders authorize reverse stock split and increase in authorized shares","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected with majority support; Hila Karah received the most 'against' votes (1.98M).","Kesselman & Kesselman (PwC) ratified as independent auditor for FY2025; 40.1M for, 146k against.","Amended 2020 Equity Compensation Plan approved; adds 6% annual share increase and authorizes RSU grants.","Reverse stock split (2:1 to 25:1) authorized; implementation by Sept 15, 2025, at Board's discretion.","Authorized common stock increased from 160M to 400M shares; approved by stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138074,"accession_number":"0001104659-25-066982","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"DarioHealth appoints Steven M. Nelson as President, retains CCO role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steven M. Nelson, 52, appointed President effective July 10, 2025, in addition to serving as Chief Commercial Officer.","Nelson has been CCO since June 2024; prior President/CEO of Contigo Health and leadership roles at Elevance Health.","No changes to his compensation per prior offer letter dated May 29, 2024, as amended.","No arrangements or transactions requiring disclosure under Item 404(a) of Regulation S-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155485,"accession_number":"0001104659-25-054236","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["1.01","3.02","3.03","5.03","9.01"],"status":"ready","headline":"DarioHealth extends preferred stock lock-up to Feb 2026; amends certificates for warrant dividends","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended lock-up agreements with Series B/C preferred holders extend restrictive period until February 21, 2026.","Holders receive additional 10% of common stock underlying preferred shares for each 3-month extension.","Company filed amended certificates for Series A-1 and B-1 preferred stock to allow dividends in pre-funded warrants.","No new securities issued under certificate amendments; provides alternative form for future dividends.","Breach of lock-up before Eligibility Date forfeits right to subsequent share consideration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155484,"accession_number":"0001104659-25-051292","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"DarioHealth extends mandatory conversion period for Series C preferred stock from 15 to 24 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mandatory conversion period extended from 15 to 24 months for Series C, C-1, C-2 preferred stock.","Preferred holders will receive a quarterly dividend of 15% of common shares issuable upon conversion.","No new securities were issued or sold as a result of the amendment.","Amended and restated certificates of designation filed on May 20, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155483,"accession_number":"0001104659-25-044809","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"DarioHealth enters $32.5M credit agreement with Callodine; warrants issued","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Borrowed $32.5M at closing; may draw up to $17.5M more subject to revenue thresholds and lender discretion.","Loan bears interest at Term SOFR + 7.75%, matures April 2030; secured by substantially all assets.","Issued warrants to purchase 2,114,140 shares at $0.8278; up to $2.5M loan principal convertible at $0.9933 per share.","Prior Loan and Security Agreement with Avenue terminated; proceeds used to satisfy LSA.","Financial covenants include minimum unencumbered liquid assets, total revenue, and Adjusted EBITDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155482,"accession_number":"0001104659-25-040182","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"DarioHealth shareholders approve up to 51.7M share issuance and warrant repricing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Vote passed 21.4M for, 0.44M against, 0.08M abstain at special meeting on April 28, 2025.","Authorizes conversion of 25,605 Series D-3 preferred shares into 33.96M common shares from Dec 2024/Jan 2025 private placements.","Also authorizes up to 13.58M common shares as dividends on Series D-3 preferred and up to 4.18M shares for lock-up agreements with B/C preferred holders.","Warrant repricing: 584,882 warrants to Avenue at $0.7208/share; loan conversion up to $2M at $0.8650/share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155481,"accession_number":"0001104659-25-036910","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2025-04-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"DarioHealth CFO Zvi Ben-David resigns; Chen Franco-Yehuda appointed CFO effective May 15, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Zvi Ben-David resigns as CFO, Treasurer, Secretary effective May 15, 2025; departure for personal reasons, not due to any disagreement.","Chen Franco-Yehuda appointed CFO, Treasurer, Secretary same date; previously CFO of Pluri Inc. (PLUR) and former PwC auditor.","New CFO receives monthly salary of approx. $22,245 (NIS 82,000), target bonus up to 6x base salary, and 500,000 RSUs vesting over three years.","Separation agreement: Ben-David joins advisory board, receives reduced monthly payments of ~$14,266 through Dec 2025 and ~$12,982 through Oct 2027.","Employment agreement includes 90-day notice period, 6-month adjustment period on termination, and 12-month non-competition covenant."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173967,"accession_number":"0001104659-25-025549","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"DarioHealth receives Nasdaq extension to Sept 15, 2025 to regain $1 bid price","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Staff granted additional 180 days until September 15, 2025 to meet Minimum Bid Price Requirement.","Must close at or above $1.00 for 10 consecutive trading days to regain compliance.","Company considering measures including a potential stock split to address the deficiency.","No assurance compliance will be achieved; failure risks delisting from Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173966,"accession_number":"0001104659-25-023589","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2025-03-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"DarioHealth dismisses EY as auditor, appoints PwC effective March 12, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["EY dismissed as independent auditor; PwC (Kesselman & Kesselman) engaged effective March 12, 2025.","No disagreements or reportable events between DarioHealth and EY in fiscal 2024 or 2023.","Company had previously consulted PwC on valuation, borrowing rates, and goodwill impairment.","EY provided a letter agreeing with the company's disclosures, filed as Exhibit 16.1.","Audit Committee of the Board approved the change."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173965,"accession_number":"0001104659-25-018230","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"DarioHealth appoints healthcare industry veteran Larry Leisure to board; director Kaplan resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lawrence Leisure appointed to board effective Feb 25, 2025; brings 40 years healthcare experience.","Jon Kaplan voluntarily resigned from board on Feb 24, 2025, no disagreement with company.","Leisure co-founded Chicago Pacific Founders; his firm NearWater has consulting agreement with Dario.","Dario entered Second Amendment to Consulting Agreement with NearWater on Feb 24, 2025, $10k monthly retainer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173964,"accession_number":"0001104659-25-005237","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2025-01-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"DarioHealth closes $25.6M private placement; targets cash flow positive by end of 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised $25.6M via convertible preferred stock at conversion prices of $0.73 and $0.83; majority from existing shareholders.","Pro forma cash balance of $40.6M as of Q3 2024; aims to achieve operational cash flow positive run rate by end of 2025.","Preferred stock pays 10% quarterly stock dividend for first four quarters; conversion subject to stockholder approval.","Lock-up agreements with Series B & C preferred holders to receive up to 40% additional common shares over 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173963,"accession_number":"0001104659-25-002576","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"DarioHealth Raises ~$6.8M via Series D Convertible Preferred Private Placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 4,974 shares of Series D-2 and 1,850 shares of Series D-3 preferred at $1,000 each for ~$6.8M gross.","Conversion price initially $0.83 per share; subject to stockholder approval; auto-convert after 12 months.","Preferred stock pays 10% quarterly dividend in common shares for four quarters after issuance.","Closing expected by January 14, 2025; securities exempt from registration under Rule 506(b)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190936,"accession_number":"0001104659-24-129777","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2024-12-18T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"DarioHealth raises ~$18.8M via preferred stock; amends Avenue loan to extend maturity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed private placement of 7,055 Series D and 11,750 Series D-1 preferred shares at $1,000 each, raising $18.8M.","Preferred stock convertible at $0.73/share, subject to stockholder approval and a 19.99% beneficial ownership blocker.","Amended Avenue loan: extended interest-only period by 6 months, conditional on revenue milestone; maturity extended to Nov 1, 2027.","Proforma cash balance of $34M as of Q3 2024; company targets profitability run-rate by end of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190935,"accession_number":"0001104659-24-129752","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2024-12-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"DarioHealth stockholders elect all 7 director nominees and ratify EY as auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven nominees elected: Hila Karah, Dennis Matheis, Dennis M. McGrath, Erez Raphael, Yoav Shaked, Jon Kaplan, and Adam K. Stern.","Each director received >15.8M votes for; broker non-votes totaled 6.67M shares.","Ratification of Kost Forer Gabbay & Kasierer (Ernst & Young) as auditor for FY2024 approved with 22.65M for, 106K against, 17.5K abstain.","Final vote tallies include preferred stock on an as-converted basis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207422,"accession_number":"0001104659-24-101690","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"DarioHealth receives Nasdaq delisting notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notice on Sept 16, 2024: closing bid price below $1.00 for 30 consecutive business days.","180-day compliance period granted until March 17, 2025 to regain compliance.","To cure, bid price must close at $1.00+ for 10 consecutive business days.","If not compliant, a second 180-day period may be available if other listing standards met.","Company will monitor bid price and consider options; no assurance of compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207421,"accession_number":"0001104659-24-099762","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2024-09-13T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"DarioHealth extends Series B-3 mandatory conversion period and increases dividends","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mandatory conversion period extended from 15 to 18 months from original issue date.","Dividends increased: 10% for fifth full quarter and 25% for sixth quarter from closing.","No additional securities were issued or sold as a result of the amendment.","Amendment effective September 11, 2024, approved by majority of preferred stock holders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224842,"accession_number":"0001104659-24-076313","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"DarioHealth amends Series B and B-1 Preferred Stock, extends conversion period, adds dividends","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mandatory conversion period extended from 15 to 18 months from original issue date.","Series B and B-1 holders get 10% dividend for fifth full quarter, 25% for sixth quarter from closing.","No additional securities were issued or sold as a result of the amendment.","Amendments filed on June 25, 2024, effective upon filing with Delaware Secretary of State."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224841,"accession_number":"0001104659-24-074740","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2024-06-25T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Stockholders approve Twill acquisition share issuance and 3M share increase to equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal 1: Approved share issuance upon exercise of warrants and RSUs from Twill acquisition and warrant re-pricing; 16,262,466 for, 1,191,420 against.","Proposal 2: Approved amendment to 2020 Plan increasing share reserve by 3,000,000 shares; 14,257,236 for, 3,156,778 against.","Both proposals required majority of votes cast; passed at the 2024 Special Meeting on June 25, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224840,"accession_number":"0001104659-24-068526","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"DarioHealth appoints Steven Nelson as CCO; President Richard Anderson departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steven Nelson, formerly CEO of Contigo Health (Premier Inc.), named Chief Commercial Officer effective June 5, 2024.","Nelson receives $400,000 base salary, annual bonus up to $400,000 tied to GAAP revenue targets (targets redacted).","Nelson granted time-vesting option for 500,000 shares and performance options for up to 400,000 (2024) and 450,000 shares (2025-2027) vested on revenue milestones.","President Richard Anderson mutually agreed to step down; no disagreement; will stay as consultant and Advisory Board member.","Anderson's departure not related to any disagreement with company's operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224839,"accession_number":"0001104659-24-050049","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2024-04-22T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"DarioHealth supplements Twill acquisition filing; Twill reports $30.7M loss, $123.6M liabilities, going concern doubt","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Twill had revenue of $18.2M in 2023, net loss of $30.7M.","Total liabilities $123.6M, total assets $9.8M; stockholders' deficit $194.3M.","Auditor expresses substantial doubt about Twill's ability to continue as a going concern.","Current liabilities of $123M far exceed current assets of $8.2M; cash and equivalents only $2.2M.","Acquisition by DarioHealth closed February 2024; this 8-K adds required pro forma financials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224838,"accession_number":"0001104659-24-049443","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2024-04-19T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"DarioHealth reduces stockholder meeting quorum to 33 1/3%","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amended Bylaws adopted April 16, 2024, lowering quorum from prior level to 33-1/3% of outstanding voting stock.","Change applies to any meeting of stockholders; reduces threshold needed to conduct business.","No other bylaw amendments disclosed; filing includes marked version showing changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224837,"accession_number":"0001104659-24-044299","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2024-04-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"DarioHealth increases CFO Zvi Ben-David's base salary to $350,000; approves up to $100k bonus for FY2024","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CFO Zvi Ben-David's base salary raised to $350,000 effective April 4, 2024.","Target annual bonus maintained at up to 40% of base salary.","Potential one-time cash bonus of up to $100,000 for fiscal year 2024, subject to Compensation Committee thresholds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244112,"accession_number":"0001104659-24-029961","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2024-03-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"DarioHealth closes $22.4M preferred stock offering with Aegis Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed offering of Series C, C-1, C-2 Preferred Stock on Feb 21, 2024.","Aggregate gross proceeds of approximately $22,422,000.","Aegis Capital Corp. acted as placement agent.","No further closings are planned for the offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244111,"accession_number":"0001104659-24-026528","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"DarioHealth posts updated investor presentation; no material new data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed updated investor presentation under Item 7.01 on Feb 22, 2024.","Presentation titled 'A Comprehensive, User-Centric Digital Health Platform' dated Feb 21, 2024.","No financial results, guidance changes, or material events were included in the filing.","Limited content from the presentation was provided in the 8-K excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244110,"accession_number":"0001104659-24-025807","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2024-02-21T23:59:59+00:00","items":["1.01","2.03","3.02","5.02","7.01","8.01","9.01"],"status":"ready","headline":"DarioHealth acquires Twill for $10M cash + ~10M pre-funded warrants; raises $22.4M PIPE","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition expected to nearly double pro forma 2023 revenue, to ~$30.5M combined.","Gross margins targeted at 80-85% by 2025; cost synergies of ~30% within two years.","Concurrent $22.4M private placement of convertible preferred stock at conversion prices $2.02/$2.14.","Tomer Ben-Kiki, Twill co-founder, appointed COO with $340K salary + stock option for 1,017,947 shares.","Twill brings customers including three of top eight national health plans and multiple Fortune 100 employers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261523,"accession_number":"0001104659-23-124996","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2023-12-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"DarioHealth annual meeting results: directors elected, say-on-pay approved, frequency set to 3 years","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected with majority support; Hila Karah received 10,656,884 votes for.","Ratification of Ernst & Young as auditor passed with 17,523,243 votes for, 497,398 against.","Issuance of dividend shares to Series B-2 preferred holders approved (12,283,574 for, 230,691 against).","Advisory vote on named executive officer compensation passed with 8,934,199 for (75% of votes cast).","Stockholders selected three years as frequency for future say-on-pay votes (5,949,982 votes for 3 years)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261522,"accession_number":"0001104659-23-109608","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2023-10-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"DarioHealth holds Investor Day; exhibit content not fully available for summary","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing announces Investor Day presentation on October 17, 2023.","Exhibit 99.1 referenced but truncated in filing excerpt; no specific figures or events extracted.","Common stock trades on Nasdaq under DRIO.","No financial results, guidance, or material updates disclosed in available filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278737,"accession_number":"0001104659-23-083237","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2023-07-24T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"DarioHealth reports preliminary Q2 revenue $6.0-6.15M, new health plan contract for 160K hypertension members","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary Q2 2023 revenue $6.0-6.15M, driven by B2B channel growth for 10th consecutive quarter.","Preliminary six-month revenue $13-13.15M; cash and equivalents $52.6M as of June 30, 2023.","New agreement with large regional health plan to provide hypertension digital solution to over 160,000 members, launching July 2023.","Strategic partnerships with MedOne (attributed to Sanofi) and Plan (attributed to Solera) expected to contribute to 2023 revenue.","Private-labeled Aetna platform delivered on schedule; member enrollment expected in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296978,"accession_number":"0001104659-23-072878","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["1.01","3.03","5.03","9.01"],"status":"ready","headline":"DarioHealth amends warrants and preferred stock certificates to remove anti-dilution price adjustments","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Removed provision in May 1, 2023 warrants that adjusted exercise price upon future equity raise below $3.334 per share.","Amended Series B, B-1, B-2, B-3 preferred stock certificates to eliminate conversion price adjustment in case of subsequent equity sale below $3.00 floor.","Removed 19.99% blocker from Series B, B-2, B-3 certificates; Series B-2 dividend shares subject to stockholder approval.","No new securities issued; changes solely to remove adjustment triggers that could dilute existing holders.","Effective June 14, 2023; filed with Delaware Secretary of State."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296976,"accession_number":"0001104659-23-057486","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K/A","filed_at":"2023-05-09T23:59:59+00:00","items":["1.01","1.02","2.03","3.02","5.03","8.01","9.01"],"status":"ready","headline":"DarioHealth amends 8-K; clarifies warrant & Series A-1 shares; closed $15.4M equity & $30M loan","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Raised $15.4M gross from sale of Series B, B-1, B-2, B-3 Preferred Stock at $1,000 per share.","Secured $30M initial tranche from Avenue Venture's $40M credit facility; interest at higher of (prime+4.5%) or 12.5%.","Issued lenders warrants for 584,884 shares at $3.334/share, 5-year term; terms clarified in this amendment.","Terminated prior OrbiMed credit agreement upon funding of new loan facility.","Series A-1 holders can earn up to 382,050 additional common shares for deferring conversion; reduced number clarified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296977,"accession_number":"0001104659-23-056519","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2023-05-05T23:59:59+00:00","items":["1.01","1.02","2.03","3.02","5.03","8.01","9.01"],"status":"ready","headline":"DarioHealth completes $15.4M preferred stock placement and $30M credit facility refinancing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised ~$15.4M via convertible preferred stock (Series B, B-1, B-2, B-3) at $1,000/share; conversion prices $3.334-$3.392.","New $30M secured credit facility from Avenue Venture Funds; $30M initial tranche closed; up to $10M additional available after July 2023.","Proforma cash $60M after transactions; expects cash runway through late 2025; saves ~$6M annually in amortization payments.","Approximately half of preferred shares bought by insiders, including management and board; Avenue receives warrant for 584,882 shares at $3.334."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317362,"accession_number":"0001104659-23-031107","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"DarioHealth confirms no cash or securities at Silicon Valley Bank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DarioHealth has no cash deposits or securities at Silicon Valley Bank.","Disclosure comes amid SVB's failure; company reassures investors of no exposure.","No financial impact expected from SVB collapse on DarioHealth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317361,"accession_number":"0001104659-23-024920","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2023-02-24T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"DarioHealth appoints Jon Kaplan to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jon Kaplan appointed to board effective February 22, 2023; board expanded by one seat.","Kaplan is Managing Director and Senior Partner at Boston Consulting Group (BCG).","Previously served on advisory boards of Livongo, Transcarent, Circulation, and Picwell.","Will receive same compensation as other non-executive directors.","Kaplan brings healthcare strategy experience; CEO cites critical timing for strategic relationships."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317360,"accession_number":"0001104659-23-010935","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2023-02-06T23:59:59+00:00","items":["2.02","2.04","7.01","9.01"],"status":"ready","headline":"DarioHealth Reports Preliminary FY2022 Revenue of $27.5M and Begins Loan Repayment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary full-year 2022 total revenue expected $27.5M, up from $20.5M in 2021.","B2B channel grew to about 60% of revenue in 2022 versus 4% in 2021.","Operating loss reduced by more than 50% compared to Q4 2021.","Credit agreement with OrbiMed triggers monthly repayments of up to $518,500 starting January 2023.","Cash and equivalents at end of 2022: $49.3 million."],"consensus_eps_estimate":null,"consensus_eps_actual":2.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":27656000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317359,"accession_number":"0001104659-23-007572","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2023-01-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"DarioHealth COO Dror Bacher terminated immediately; advisory role and reduced salary through May 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["COO Dror Bacher terminated effective Jan 23, 2023; retained as advisory board member.","Monthly salary reduced to 42,137 NIS (~$12,504) from Feb 2023 through May 2025.","Subject to Compensation Committee approval, 75,000 restricted shares granted, vesting quarterly through Dec 2024.","Non-compete clause with 12-month post-termination restriction; specific competitors listed (Livongo, Omada, Virta, Vida)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317358,"accession_number":"0001104659-23-003840","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2023-01-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"DarioHealth settles stockholder class action over director removal bylaw; pays $75K in fees","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settled Chavakula v. DarioHealth Corp. challenging a bylaw allowing board to remove directors with/without cause.","Company agreed not to use the Removal Provision to remove a director.","DarioHealth pays $75,000 in attorneys' fees/expenses plus $500 service award to plaintiff.","Court closed case on Jan 9, 2023 after company issued this notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335598,"accession_number":"0001104659-22-125205","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2022-12-07T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"DarioHealth stockholders approve amendment to 2020 Equity Incentive Plan increasing share reserve","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved Plan Amendment increasing 2020 Plan share reserve to 3,868,514 shares plus annual evergreen increase of 6% of outstanding fully diluted shares for 2021-2025.","All six director nominees elected: Hila Karah, Dennis Matheis, Dennis McGrath, Erez Raphael, Yoav Shaked, Adam K. Stern.","Ratification of Kost Forer Gabbay & Kasierer as independent auditor for FY2022 approved with 15.38M for, 1.92M against.","Plan Amendment was previously approved by Board on October 3, 2022, subject to stockholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335597,"accession_number":"0001104659-22-105259","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2022-10-03T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"DarioHealth sets 2022 annual meeting for Dec 7, record date Oct 13","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting scheduled for Dec 7, 2022 at 4:00 p.m. Israel time at Caesarea office.","Record date for voting eligibility is Oct 13, 2022.","Stockholder proposals for inclusion in proxy materials due by Oct 13, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353034,"accession_number":"0001104659-22-090461","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2022-08-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"DarioHealth Q2 revenue $6.2M (+17.5% YoY); net loss $18M; strategic shift to B2B2C","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $6.2M, up 17.5% YoY but down 23.3% sequentially; gross margin 18.4% (pro-forma 36.1%).","Net loss $18.0M vs $17.8M in Q2 2021; operating loss $17.4M; cash $68M.","B2B2C contract value totals $55M; new national health plan deal providing reach to ~10M members.","Strategic decision to reduce DTC focus and prioritize B2B2C channels, cutting customer acquisition costs 70%.","Secured up to $50M non-dilutive credit facility with OrbiMed; on track to exceed 100 B2B2C contracts by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":1.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":14242000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370675,"accession_number":"0001104659-22-070560","cik":1533998,"company_name":"DarioHealth Corp.","ticker":"DRIO","form_type":"8-K","filed_at":"2022-06-13T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"DarioHealth secures $50M non-dilutive credit facility with OrbiMed; $25M drawn at close","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$50M senior secured term loan from OrbiMed; $25M funded at closing, $25M available before June 30, 2023 subject to revenue thresholds.","Interest rate: adjusted SOFR + 9.50% (floor 0.50%); warrants issued for 226,586 shares at $6.62, 7-year term.","CEO states cash runway potentially >$100M, enabling multi-year business plan without further capital raises.","Facility is non-dilutive, supports B2B segment growth and platform development.","Obligations secured by substantially all assets; $10M minimum unrestricted cash covenant; subsidiary guarantees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":58316372.39285714,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-06-13T23:59:59+00:00|370675"}